Abstract
The interest for acetylcholinesterase as a target for the palliative treatment of Alzheimers disease has been renewed in the last years owing to the evidences that support the role of this enzyme in accelerating the aggregation and deposition of the β-amyloid peptide. A large amount of structural information on the acetylcholinesterase enzyme and of its complexes with inhibitors acting at the catalytic site, the peripheral binding site, or both is now available. Based on that, molecular modelling studies can be intensively used to decipher the molecular determinants that mediate the relationship between chemical structure and inhibitory potency. In turn, this knowledge can be exploited to design new compounds leading to more effective cholinergic strategies. At this point, inhibitors able to interact at the peripheral binding site are of particular relevance, as they might disrupt the interactions between the enzyme acetylcholinesterase and the β-amyloid peptide. Therefore, these compounds might not only ameliorate the cholinergic deficit, but also be capable of slowing down the progression of the disease.
Keywords: alzheimers disease, cholinesterase inhibitors, molecular modelling, structure-activity relationships
Current Pharmaceutical Design
Title: Molecular Modelling Approaches to the Design of Acetylcholinesterase Inhibitors: New Challenges for the Treatment of Alzheimers Disease
Volume: 10 Issue: 25
Author(s): J. Munoz-Muriedas, J. M. Lopez, Modesto Orozco and F. Javier Luque
Affiliation:
Keywords: alzheimers disease, cholinesterase inhibitors, molecular modelling, structure-activity relationships
Abstract: The interest for acetylcholinesterase as a target for the palliative treatment of Alzheimers disease has been renewed in the last years owing to the evidences that support the role of this enzyme in accelerating the aggregation and deposition of the β-amyloid peptide. A large amount of structural information on the acetylcholinesterase enzyme and of its complexes with inhibitors acting at the catalytic site, the peripheral binding site, or both is now available. Based on that, molecular modelling studies can be intensively used to decipher the molecular determinants that mediate the relationship between chemical structure and inhibitory potency. In turn, this knowledge can be exploited to design new compounds leading to more effective cholinergic strategies. At this point, inhibitors able to interact at the peripheral binding site are of particular relevance, as they might disrupt the interactions between the enzyme acetylcholinesterase and the β-amyloid peptide. Therefore, these compounds might not only ameliorate the cholinergic deficit, but also be capable of slowing down the progression of the disease.
Export Options
About this article
Cite this article as:
Munoz-Muriedas J., Lopez M. J., Orozco Modesto and Luque Javier F., Molecular Modelling Approaches to the Design of Acetylcholinesterase Inhibitors: New Challenges for the Treatment of Alzheimers Disease, Current Pharmaceutical Design 2004; 10 (25) . https://dx.doi.org/10.2174/1381612043383386
DOI https://dx.doi.org/10.2174/1381612043383386 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Links Between Endothelial Dysfunction and Neurodegeneration in Alzheimer's Disease
Current Alzheimer Research Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Maternal Fish Oil Supplementation: The Prodrom of Synaptic Protection in Alzheimers Disease
Current Nutrition & Food Science Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI) Patients are Characterized by Increased BDNF Serum Levels
Current Alzheimer Research Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging PLA2G6 Mutations and Other Rare Causes of Neurodegeneration with Brain Iron Accumulation
Current Drug Targets Running Exercise Reduces Myelinated Fiber Loss in the Dentate Gyrus of the Hippocampus in APP/PS1 Transgenic Mice
Current Alzheimer Research Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Efficient and Green Synthetic Protocol for the Synthesis of Structurally Diverse Spiroheterocycles using GAAS as Catalytic Solvent
Current Organocatalysis